Interferon induced thyroiditis

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 23, Issue 6, 2009, Pages 703-712

  Tomer, Yaron ^a,b   Menconi, Francesca ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

autoimmunity; interferon; thyroiditis

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; RADIOACTIVE IODINE; THYROID ANTIBODY; THYROID HORMONE; THYROID PEROXIDASE ANTIBODY;

AUTOIMMUNITY; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; EARLY DIAGNOSIS; GENETIC SUSCEPTIBILITY; GRAVES DISEASE; HASHIMOTO DISEASE; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; NONHUMAN; REVIEW; RISK FACTOR; THYROID SURGERY; THYROIDITIS; THYROTOXICOSIS;

GENETIC PREDISPOSITION TO DISEASE; GRAVES DISEASE; HASHIMOTO DISEASE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; THYROID GLAND; THYROIDITIS; THYROIDITIS, AUTOIMMUNE;

EID: 71749102011     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2009.07.004     Document Type: Review

References (84)

1. Pfeffer L.M., Dinarello C.A., Herberman R.B., et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Research 58 12 (1998) 2489-2499
2. Parmar S., and Platanias L.C. Interferons: mechanisms of action and clinical applications. Current Opinion in Oncology 15 6 (2003) 431-439
3. Jonasch E., and Haluska F.G. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6 1 (2001) 34-55
4. Baron S., Tyring S.K., Fleischmann Jr. W.R., et al. The interferons. Mechanisms of action and clinical applications. The Journal of the American Medical Association 266 10 (1991) 1375-1383
5. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine 347 13 (2002) 975-982
6. Russo M.W., and Fried M.W. Side effects of therapy for chronic hepatitis C. Gastroenterology 124 6 (2003) 1711-1719
7. Fentiman I.S., Thomas B.S., Balkwill F.R., et al. Primary hypothyroidism associated with interferon therapy of breast cancer. Lancet 1 8438 (1985) 1166
8. Prummel M.F., and Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid 13 6 (2003) 547-551
9. Koh L.K., Greenspan F.S., and Yeo P.P. Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid 7 6 (1997) 891-896
10. Roti E., Minelli R., Giuberti T., et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. American Journal of Medicine 101 5 (1996) 482-487
11. Mazziotti G., Sorvillo F., Stornaiuolo G., et al. Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: a prospective study. Journal of Endocrinological Investigation 25 7 (2002) 624-630
12. Mandac J.C., Chaudhry S., Sherman K.E., et al. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology 43 4 (2006) 661-672
13. Martocchia A., Labbadia G., Paoletti V., et al. Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease. Neuro Endocrinology Letters 22 1 (2001) 49-52
14. Baudin E., Marcellin P., Pouteau M., et al. Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C. Clinical Endocrinology 39 6 (1993) 657-661
15. Carella C., Mazziotti G., Morisco F., et al. Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. The Journal of Clinical Endocrinology and Metabolism 86 5 (2001) 1925-1929
16. Watanabe U., Hashimoto E., Hisamitsu T., et al. The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. The American Journal of Gastroenterology 89 3 (1994) 399-403
17. Preziati D., La Rosa L., Covini G., et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. European Journal of Endocrinology 132 5 (1995) 587-593
18. Imagawa A., Itoh N., Hanafusa T., et al. Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepatitis. The Journal of Clinical Endocrinology and Metabolism 80 3 (1995) 922-926
19. Wong V., Fu A.X., George J., et al. Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clinical Endocrinology 56 6 (2002) 793-798
20. Lisker-Melman M., Di Bisceglie A.M., Usala S.J., et al. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 102 6 (1992) 2155-2160
21. Villanueva R.B., and Brau N. Graves' ophthalmopathy associated with interferon-alpha treatment for hepatitis C. Thyroid 12 8 (2002) 737-738
22. Hollowell J.G., Staehling N.W., Flanders W.D., et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). The Journal of Clinical Endocrinology and Metabolism 87 2 (2002) 489-499
23. Vanderpump M.P.J., Tunbridge W.M.G., French J.M., et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham survey. Clinical Endocrinology 43 (1995) 55-68
24. Ban Y., Greenberg D.A., Davies T.F., et al. Linkage analysis of thyroid antibody production: evidence for shared susceptibility to clinical autoimmune thyroid disease. The Journal of Clinical Endocrinology and Metabolism 93 9 (2008) 3589-3596
25. Carella C., Amato G., Biondi B., et al. Longitudinal study of antibodies against thyroid in patients undergoing interferon-alpha therapy for HCV chronic hepatitis. Hormone Research 44 3 (1995) 110-114
26. Marazuela M., Garcia-Buey L., Gonzalez-Fernandez B., et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clinical Endocrinology 44 6 (1996) 635-642
27. Weetman A.P., Smallridge R.C., Nutman T.B., et al. Persistent thyroid autoimmunity after subacute thyroiditis. Journal of Clinical & Laboratory Immunology 23 (1987) 1-6
28. Parana R., Cruz M., Lyra L., et al. Subacute thyroiditis during treatment with combination therapy (interferon plus ribavirin) for hepatitis C virus. Journal of Viral Hepatitis 7 5 (2000) 393-395
29. Bohbot N.L., Young J., Orgiazzi J., et al. Interferon-alpha-induced hyperthyroidism: a three-stage evolution from silent thyroiditis towards Graves' disease. European Journal of Endocrinology 154 3 (2006) 367-372
30. Nguyen K.B., Watford W.T., Salomon R., et al. Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science 297 5589 (2002) 2063-2066
31. Corssmit E.P., de Metz J., Sauerwein H.P., et al. Biologic responses to IFN-alpha administration in humans. Journal of Interferon & Cytokine Research 20 12 (2000) 1039-1047
32. You X., Teng W., and Shan Z. Expression of ICAM-1, B7.1 and TPO on human thyrocytes induced by IFN-alpha. Chinese Medical Journal 112 1 (1999) 61-66
33. Farrar J.D., and Murphy K.M. Type I interferons and T helper development. Immunology Today 21 10 (2000) 484-489
34. Tilg H. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 112 3 (1997) 1017-1021
35. Mazziotti G., Sorvillo F., Piscopo M., et al. Innate and acquired immune system in patients developing interferon-alpha-related autoimmune thyroiditis: a prospective study. The Journal of Clinical Endocrinology and Metabolism 90 7 (2005) 4138-4144
36. Land K.J., Moll J.S., Kaplan M.H., et al. Signal transducer and activator of transcription (Stat)-6-dependent, but not Stat4-dependent, immunity is required for the development of autoimmunity in Graves' hyperthyroidism. Endocrinology 145 8 (2004) 3724-3730
37. Mazziotti G., Sorvillo F., Carbone A., et al. Is the IFN-alpha-related thyroid autoimmunity an immunologically heterogeneous disease?. Journal of Internal Medicine 252 4 (2002) 377-378
38. Nagayama Y., Mizuguchi H., Hayakawa T., et al. Prevention of autoantibody-mediated Graves'-like hyperthyroidism in mice with IL-4, a Th2 cytokine. Journal of Immunology 170 7 (2003) 3522-3527
39. Corssmit E.P., Heijligenberg R., Hack C.E., et al. Effects of interferon-alpha (IFN-alpha) administration on leucocytes in healthy humans. Clinical and Experimental Immunology 107 2 (1997) 359-363
40. Ajjan R.A., Watson P.F., McIntosh R.S., et al. Intrathyroidal cytokine gene expression in Hashimoto's thyroiditis. Clinical and Experimental Immunology 105 3 (1996) 523-528
41. Krause I., Valesini G., Scrivo R., et al. Autoimmune aspects of cytokine and anticytokine therapies. American Journal of Medicine 115 5 (2003) 390-397
42. Lindahl P., Leary P., and Gresser I. Enhancement by interferon of the expression of surface antigens on murine leukemia L 1210 cells. Proceedings of the National Academy of Sciences of the United States of America 70 10 (1973) 2785-2788
43. Caraccio N., Giannini R., Cuccato S., et al. Type I interferons modulate the expression of thyroid peroxidase, sodium/iodide symporter, and thyroglobulin genes in primary human thyrocyte cultures. The Journal of Clinical Endocrinology and Metabolism 90 2 (2005) 1156-1162
44. Akeno N, Tomer Y. Dissecting the mechanisms of interferon induced thyroiditis (IIT): direct effects of interferon alpha on thyroid epithelial cells. The 89th meeting of the Endocrine Society, Toronto, Canada, June 2007. 2007.
45. Caraccio N., Cuccato S., Pratesi F., et al. Effect of type I interferon(s) on cell viability and apoptosis in primary human thyrocyte cultures. Thyroid 19 2 (2009) 149-155
46. Kryczka W., Brojer E., Kowalska A., et al. Thyroid gland dysfunctions during antiviral therapy of chronic hepatitis C. Medical Science Monitor 7 Suppl. 1 (2001) 221-225
47. Deutsch M., Koskinas J., Tzannos K., et al. Hashimoto encephalopathy with pegylated interferon alfa-2b and ribavirin. The Annals of Pharmacotherapy 39 10 (2005) 1745-1747
48. Rotondi M., Minelli R., Magri F., et al. Serum CXCL10 levels and occurrence of thyroid dysfunction in patients treated with interferon-{alpha} therapy for hepatitis C virus-related hepatitis. European Journal of Endocrinology 156 4 (2007) 409-414
49. Weetman A.P. Graves' disease. New England Journal of Medicine 343 17 (2000) 1236-1248
50. Tomer Y., and Davies T.F. Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. Endocrine Reviews 24 (2003) 694-717
51. Huber A., Menconi F., Corathers S., et al. Joint genetic susceptibility to type 1 diabetes and autoimmune thyroiditis: from epidemiology to mechanisms. Endocrine Reviews 29 6 (2008) 697-725
52. Dalgard O., Bjoro K., Hellum K., et al. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. Journal of Internal Medicine 251 5 (2002) 400-406
53. Grossman C.J., Roselle G.A., and Mendenhall C.L. Sex steroid regulation of autoimmunity. The Journal of Steroid Biochemistry and Molecular Biology 40 4-6 (1991) 649-659
54. Oppenheim Y., Kim G., Ban Y., et al. The effects of alpha interferon on the development of autoimmune thyroiditis in the NOD H2h4 mouse. Clinical & Developmental Immunology 10 2-4 (2003) 161-165
55. Jacobson E.M., and Tomer Y. The CD40, CTLA-4, thyroglobulin, TSH receptor, and PTPN22 gene quintet and its contribution to thyroid autoimmunity: back to the future. Journal of Autoimmunity 28 (2007) 85-98
56. Stenszky V., Kozma L., Balazs C., et al. The genetics of Graves' disease: HLA and disease susceptibility. The Journal of Clinical Endocrinology and Metabolism 61 (1985) 735-740
57. Ban Y., Davies T.F., Greenberg D.A., et al. Arginine at position 74 of the HLA-DRb1 chain is associated with Graves' disease. Genes and Immunity 5 (2004) 203-208
58. Yanagawa T., Hidaka Y., Guimaraes V., et al. CTLA-4 gene polymorphism associated with Graves' disease in a caucasian population. The Journal of Clinical Endocrinology and Metabolism 80 (1995) 41-45
59. Vaidya B., Imrie H., Perros P., et al. The cytotoxic T lymphocyte antigen-4 is a major Graves' disease locus. Human Molecular Genetics 8 7 (1999) 1195-1199
60. Tomer Y., Greenberg D.A., Barbesino G., et al. CTLA-4 and not CD28 is a susceptibility gene for thyroid autoantibody production. The Journal of Clinical Endocrinology and Metabolism 86 (2001) 1687-1693
61. Smyth D., Cooper J.D., Collins J.E., et al. Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes 53 11 (2004) 3020-3023
62. Velaga M.R., Wilson V., Jennings C.E., et al. The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease. The Journal of Clinical Endocrinology and Metabolism 89 11 (2004) 5862-5865
63. Ban Y., Greenberg D.A., Concepcion E., et al. Amino acid substitutions in the thyroglobulin gene are associated with susceptibility to human and murine autoimmune thyroid disease. Proceedings of the National Academy of Sciences of the United States of America 100 (2003) 15119-15124
64. Hiratani H., Bowden D.W., Ikegami S., et al. Multiple SNPs in intron 7 of thyrotropin receptor are associated with Graves' disease. The Journal of Clinical Endocrinology and Metabolism 90 5 (2005) 2898-2903
65. Kakizaki S., Takagi H., Murakami M., et al. HLA antigens in patients with interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. Journal of Hepatology 30 5 (1999) 794-800
66. Jacobson E.M., Chaudhry S., Mandac J.C., et al. Immune-regulatory gene involvement in the etiology of interferon induced thyroiditis (IIT). Thyroid 16 (2006) 926
67. Oppenheim Y., Ban Y., and Tomer Y. Interferon induced Autoimmune Thyroid Disease (AITD): a model for human autoimmunity. Autoimmunity Reviews 3 5 (2004) 388-393
68. Tomer Y., and Davies T.F. Infection, thyroid disease and autoimmunity. Endocrine Reviews 14 (1993) 107-120
69. Tomer Y., and Villanueva R. Hepatitis C and thyroid autoimmunity: is there a link?. American Journal of Medicine 117 1 (2004) 60-61
70. Loviselli A., Oppo A., Velluzzi F., et al. Independent expression of serological markers of thyroid autoimmunity and hepatitis virus C infection in the general population: results of a community-based study in north-western Sardinia. Journal of Endocrinological Investigation 22 9 (1999) 660-665
71. Metcalfe R.A., Ball G., Kudesia G., et al. Failure to find an association between hepatitis C virus and thyroid autoimmunity. Thyroid 7 3 (1997) 421-424
72. Boadas J., Rodriguez-Espinosa J., Enriquez J., et al. Prevalence of thyroid autoantibodies is not increased in blood donors with hepatitis C virus infection. Journal of Hepatology 22 6 (1995) 611-615
73. Tran A., Quaranta J.F., Benzaken S., et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology 18 2 (1993) 253-257
74. Ganne-Carrie N., Medini A., Coderc E., et al. Latent autoimmune thyroiditis in untreated patients with HCV chronic hepatitis: a case-control study. Journal of Autoimmunity 14 2 (2000) 189-193
75. Fernandez-Soto L., Gonzalez A., Escobar-Jimenez F., et al. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Archives of Internal Medicine 158 13 (1998) 1445-1448
76. Antonelli A., Ferri C., Pampana A., et al. Thyroid disorders in chronic hepatitis C. American Journal of Medicine 117 1 (2004) 10-13
77. Indolfi G., Stagi S., Bartolini E., et al. Thyroid function and anti-thyroid autoantibodies in untreated children with vertically acquired chronic hepatitis C virus infection. Clinical Endocrinology 68 1 (2008) 117-121
78. Antonelli A., Ferri C., Fallahi P., et al. Thyroid disorders in chronic hepatitis C virus infection. Thyroid 16 6 (2006) 563-572
79. Bartolome J., Rodriguez-Inigo E., Quadros P., et al. Detection of hepatitis C virus in thyroid tissue from patients with chronic HCV infection. Journal of Medical Virology 80 9 (2008) 1588-1594
80. Munshi N., Balasubramanian A., Koziel M., et al. Hepatitis C and human immunodeficiency virus envelope proteins cooperatively induce hepatocytic apoptosis via an innocent bystander mechanism. The Journal of Infectious Diseases 188 8 (2003) 1192-1204
81. Balasubramanian A., Ganju R.K., and Groopman J.E. Signal transducer and activator of transcription factor 1 mediates apoptosis induced by hepatitis C virus and HIV envelope proteins in hepatocytes. The Journal of Infectious Diseases 194 5 (2006) 670-681
82. Balasubramanian A., Ganju R.K., and Groopman J.E. Hepatitis C virus and HIV envelope proteins collaboratively mediate interleukin-8 secretion through activation of p38 MAP kinase and SHP2 in hepatocytes. The Journal of Biological Chemistry 278 37 (2003) 35755-35766
83. Akeno N., Blackard J.T., and Tomer Y. HCV E2 protein binds directly to thyroid cells and induces IL-8 production: a new mechanism for HCV induced thyroid autoimmunity. The Journal of Autoimmunity 31 4 (2008) 339-344
84. Tomer Y., Blackard J.T., and Akeno N. Interferon alpha treatment and thyroid dysfunction. Endocrinology and Metabolism Clinics of North America 36 4 (2007) 1051-1066